BIOCON391.00

Biocon Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYSYNGENEMANKINDGLENMARKLAURUSLABSALKEMLUPINMcap ₹63,381 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)355.79420.85420.89420.89
Receivable Days (DSO)154.12131.25129.09129.09
Payable Days (DPO)451.37558.91468.36451.25
Cash Conversion Cycle (days)58.54-6.8181.6298.73
Working Capital Turnover-82.167.825.445.57
Asset Turnover0.260.260.270.27
Cash Conversion (CFO/Net Income)2.282.845.415.41
CFO/EBITDA0.901.280.580.58
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.